BGNE - BeiGene Ltd Stock Price, Fair Value and News

$181.62+3.92 (+2.21%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BGNE Price Action

Last 7 days

1.4%

Last 30 days

-4.7%

Last 90 days

-12.1%

Trailing 12 Months

3.1%

BGNE RSI Chart

BGNE Valuation

Market Cap

251.7B

Price/Earnings (Trailing)

-292.56

Price/Sales (Trailing)

75.9

EV/EBITDA

-431.37

Price/Free Cashflow

-253.11

BGNE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

3.3B

Rev. Growth (Yr)

28.2%

Rev. Growth (Qtr)

7.8%

BGNE Earnings

Earnings (TTM)

-860.5M

Earnings Growth (Yr)

-156.33%

Earnings Growth (Qtr)

-0.78%

BGNE Profitability

EBT Margin

-24.07%

Return on Equity

-25.04%

Return on Assets

-14.76%

Free Cashflow Yield

-0.4%

BGNE Investor Care

Shares Dilution (1Y)

1.95%

Diluted EPS (TTM)

-0.63

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.8B	3.1B	3.3B	0
2023	1.6B	1.8B	2.2B	2.5B
2022	877.0M	1.1B	1.2B	1.4B
2021	862.7M	947.0M	1.1B	1.2B
2020	402.4M	224.7M	265.7M	308.9M
2019	243.5M	434.1M	430.0M	428.2M
2018	281.1M	323.7M	157.7M	198.2M
2017	0	0	180.6M	238.4M
2016	8.1M	7.1M	64.9M	122.8M
2015	12.0M	10.9M	9.9M	8.8M
2014	0	0	0	13.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About BeiGene Ltd

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

CEO	Mr. John V. Oyler
WEBSITE	beigene.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	10000

BeiGene Ltd Frequently Asked Questions

What is the ticker symbol for BeiGene Ltd? What does BGNE stand for in stocks?

BGNE is the stock ticker symbol of BeiGene Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BeiGene Ltd (BGNE)?

As of Tue Dec 24 2024, market cap of BeiGene Ltd is 251.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BGNE stock?

You can check BGNE's fair value in chart for subscribers.

Is BeiGene Ltd a good stock to buy?

The fair value guage provides a quick view whether BGNE is over valued or under valued. Whether BeiGene Ltd is cheap or expensive depends on the assumptions which impact BeiGene Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BGNE.

What is BeiGene Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, BGNE's PE ratio (Price to Earnings) is -292.56 and Price to Sales (PS) ratio is 75.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGNE PE ratio will change depending on the future growth rate expectations of investors.